Trial Profile

A Pivotal Clinical Trial of MB-107 in Newly Diagnosed Infants with X-Linked Severe Combined Immunodeficiency (XSCID)

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 31 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MB 107 (Primary)
Indications Immunodeficiency disorders; X-linked genetic disorders
Focus Registrational; Therapeutic Use
Acronyms RESTORE
Sponsors Mustang Bio

Most Recent Events

28 Mar 2022 According to a Mustang Bio media release, the company expect to enroll first patient in the second half of 2022.
02 Aug 2021 According to a Mustang Bio media release, the company prepare to initiate this study at the end of this quarter.
24 Mar 2021 According to a Mustang Bio media release, the company plans to begin enrollment in second quarter of 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com